Key Highlights

  • The quarter closed with a USD 297.1 million net loss, equal to USD 1.99 per share, a sharp increase from the USD 212.8 million (USD 1.56 per share) recorded a year before.
  • Research spending rose 28.8% to USD 270.3 million, of which USD 130.9 million went to Manufacturing and USD 38.4 million to clinical trials.
  • At September 30, 2026 the company held USD 0.1 billion in cash and USD 2.1 billion in investments, before convertible note sales of USD 575 million in October.
  • VAX-31 hit all prespecified primary targets in the pivotal OPUS-1 adult study, which covered 3,572 people aged 50 and up.

Loss Widens as Phase 3 Trials and Manufacturing Scale Up

Vaxcyte (NASDAQ:PCVX) submitted its Quarterly Report on November 4, 2026, covering the period through September 30. Without product sales, it reports no revenue, so its USD 308.3 million operating loss equals total operating outlays, which grew 27.2%. The net loss expanded 39.6% to USD 297.1 million. Other income, net came down to USD 11.2 million from USD 29.6 million, with currency gains lower by USD 12.0 million and interest income down USD 6.1 million. Administrative spending increased 17.0% to USD 37.9 million, driven by staffing and consultants. Over the first nine months the net loss totaled USD 902.0 million, or USD 6.25 per share, up from USD 520.1 million, or USD 3.83 per share.

Where the Money Goes: VAX-31 Trials and Launch Preparation

Production costs climbed USD 20.2 million, a change the filing links to preparation for potential commercial launches. Clinical expenses went up USD 18.7 million across three Phase 3 studies named OPUS-1, OPUS-2 and OPUS-3. The company develops broad-spectrum pneumococcal conjugate vaccines through a cell-free protein synthesis approach. In OPUS-1, every one of the 28 VAX-31 serotypes that overlap with Prevnar 20 or Capvaxive achieved noninferiority, yet serotypes 3 and 12F fell short of the tougher benchmark set against Capvaxive and only satisfied a historical standard. Safety profiles resembled those of comparator vaccines, and regulators granted VAX-31 breakthrough therapy status in adults. Results from OPUS-2 and OPUS-3, together with the infant Phase 2 study, are anticipated during the first half of 2027.

Financing Runway, Share Issuance and the 2032 Convertible Notes

Management believes existing cash, equivalents and investments will support operations for a minimum of 12 months from the filing date, although completing development and commercial launch will Demand substantially more capital. In February 2026 the company placed 12,650,000 shares at USD 50.00, generating net proceeds of USD 601.8 million. October brought a second offering of 8,584,375 shares at USD 64.00, along with USD 575 million of 1.50% convertible notes maturing in 2032 that carry an initial conversion price close to USD 89.60. Shares outstanding increased to 149.3 million from 131.1 million at the start of the year. Only the USD 500 million at-the-market program remains untapped, and non-cancelable manufacturing obligations reach USD 524.4 million, against an accumulated Deficit of USD 3.1 billion.

Where Things Stand

The loss is funding Phase 3 execution and launch readiness, chiefly through research and manufacturing outlays. Vaxcyte (NASDAQ:PCVX) continues to face a growing loss, ongoing share dilution and regulatory milestones, including a lot-to-lot consistency study that must come before a Biologics License Application. Investors should track the OPUS-2 and OPUS-3 readouts, the infant Phase 2 data expected in the first half of 2027, and how the October financing appears in the next balance sheet.